- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05855122
Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
June 1, 2023 updated by: Fu chengcheng PhD, The First Affiliated Hospital of Soochow University
Study of Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following High-dose Melphalan Conditioning in Patients With Multiple Myeloma
Background: Autologous hematopoietic stem cell transplantation(ASCT) is an important part treatment for patients with multiple myeloma.
Retrospective analysis from our center showed that incidence of oral mucositis and gastrointestinal symptoms was higher during ASCT for melphalan as conditioning regimen in patients with multiple myeloma.
Objective: Safety and optimization of ASCT-related symptom burden of tocilizumab for melphalan as a conditioning regimen in ASCT for multiple myeloma is explored.
Methods: The patient who is enrolled will be randomly divided into two groups in a proportion of 1:1 to respectively receive tocilizumab(8mg/kg) at day -7 before transfusion of stem cells or not.
There will be enroll 48 patients according to inclusion and exclusion criteria totally.
Adverse events and MDASI score during ASCT between two groups will be recorded and analyzed.
Primary endpoint: MDASI, Security; Secondary endpoints: time to neutrophil engraftment; time of platelet implantation; efficacy (ORR) after autologous hematopoietic stem cell transplantation.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
48
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: chengcheng Fu, PhD
- Phone Number: 051267781856
- Email: fuzhengzheng@suda.edu.cn
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215006
- Recruiting
- The First Affiliated Hospital of Soochow University
-
Contact:
- chengcheng Fu
- Phone Number: 0512-67781856
- Email: fuzhengzheng@suda.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with multiple myeloma eligible for autologous hematopoietic stem cell transplantation;
Secretory MM should have measurable markers, including:
- specific M protein value (≥5g/L);
- and/or involved flc ≥100mg/L;
- and/or measurable extramedullary foci (diameter>1cm on CT);
- Age ≥ 18 years and ≤ 70 years, male or female;
- PR and above are obtained after induction therapy according to the IMWG response criteria;
- Mononuclear cells ≥2×10^8/kg body weight, CD34+ cells≥2×10^6/kg body weight;
- ECOG 0-2, with life expectance ≥3 months;
- ALT/AST level ≤2.5 times of the maximum of normal range; total bilirubin≤2 times of normal maximum;
- Neutrophil count≥ 1.5×10^9/L, platelet count ≥50×10^9/L;
- Normal Left ventricular ejection fraction , NYHA stage 1, lung function GOLD stage 1;
- Willing to accept the possibility of potential adverse events and efficacy observation by the investigators;
- Being able to understand and signing the written consent, which should be signed prior to any procedure of the trial.
Exclusion Criteria:
- With ≥2 degree of peripheral neuropath or with pain;
- Having received any of the medicine of the experiment regimen within 30 days prior to enrollment, pain-relieving radiotherapy is allowed;
- With severe pulmonary/cardiac disfunction (including history of QT interval elongation, ventricular tachycardia, ventricular fibrillation, myocardial infraction) or other severe organ malfunction;
- Patients in pregnancy or lactation;
- Allergic constitution or being allergic to any drug within the regimen of the trial;
- With uncontrolled mental diseases;
- With active infection;
- With active hepatitis;
- HIV positive;
- History of other malignant tumor within 5 years prior to enrollment; except for the case of in situ cervical cancer and non-malignant melanoma;
- With other conditions that the investigators think unfit for the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tocilizumab
|
Pateients enrolled in Tocilizumab group will receive tocilizumab(8mg/kg) at day -7 before transfusion of stem cells.
|
No Intervention: no-Tocilizumab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: day -7~day 100 after stem cells transfusion
|
recording adverse events according to CTCAE5.0
|
day -7~day 100 after stem cells transfusion
|
MDASI questionnaire
Time Frame: day -7~day 100 after stem cells transfusion
|
MDASI, also as the M. D. Anderson Symptom Inventory, is a brief measure of the severity and impact of cancer related symptoms.
Each symptom is rated on an 11-point scale (0 -10) to indicate the presence and severity of the symptom, with 0 meaning "not present" and 10 meaning "as bad as you can imagine."
Each symptom is rated at its worst in the last 24 hours.
|
day -7~day 100 after stem cells transfusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 17, 2023
Primary Completion (Estimated)
August 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
May 3, 2023
First Submitted That Met QC Criteria
May 3, 2023
First Posted (Actual)
May 11, 2023
Study Record Updates
Last Update Posted (Estimated)
June 2, 2023
Last Update Submitted That Met QC Criteria
June 1, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- Tocilizumab-ASCT-MM08
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Tocilizumab
-
University of ChicagoActive, not recruiting
-
CelltrionNot yet recruiting
-
University of ChicagoRecruiting
-
Reade Rheumatology Research InstituteZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruitingRheumatoid ArthritisNetherlands
-
Memorial Sloan Kettering Cancer CenterTerminatedCOVID-19United States
-
University of ChicagoCompleted
-
Karadeniz Technical UniversityCompletedCOVID-19 | Mortality | Critical Care | TocilizumabTurkey
-
Assistance Publique - Hôpitaux de ParisUnknown
-
Università Politecnica delle MarcheAzienda Ospedaliera Ospedali Riuniti Marche NordUnknown
-
Hospital of PratoUnknown